Publications by authors named "Markus Lucerna"

Claim this Profile
E
European experience of patients with HER2-positive advanced/metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: the EUROPA T-DXd study.
Cristina Saura, Hans Wildiers, Giampaolo Bianchini, José Ángel García-Saenz, Arthur Allignol, Markus Lucerna

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
Paul Cottu, Sue Cheeseman, Peter Hall, Achim Wöckel, Christian W Scholz, Markus Lucerna

Breast Cancer Res Treat· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer.
Valentina Guarneri, José Luís Passos Coelho, Francois P Duhoux, Daniel Egle, José Ángel García-Sáenz, Markus Lucerna

Future Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry.
Giulia Renda, Ladislav Pecen, Giuseppe Patti, Fabrizio Ricci, Dipak Kotecha, Markus Lucerna

Intern Emerg Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
Giuseppe Patti, Ladislav Pecen, Markus Lucerna, Kurt Huber, Miklos Rohla

Am J Med· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Miklos Rohla, Thomas W Weiss, Ladislav Pecen, Giuseppe Patti, Jolanta M Siller-Matula, Markus Lucerna

BMJ Open· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.
Giuseppe Patti, Ladislav Pecen, Markus Lucerna, Kurt Huber, Miklos Rohla

Int J Cardiol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes.
Renate B Schnabel, Ladislav Pecen, Daniel Engler, Markus Lucerna, Jean Marc Sellal

Heart· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.
Jolanta M Siller-Matula, Ladislav Pecen, Giuseppe Patti, Markus Lucerna, Paulus Kirchhof

Int J Cardiol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe.
Renate B Schnabel, Ladislav Pecen, Nargiz Rzayeva, Markus Lucerna, Yanish Purmah

J Am Heart Assoc· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
Raffaele De Caterina, Bernd Brüggenjürgen, Harald Darius, Sabine Köhler, Markus Lucerna

Arch Cardiovasc Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation.
Renate B Schnabel, Ladislav Pecen, Francisco M Ojeda, Markus Lucerna, Nargiz Rzayeva

Heart· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation).
Giuseppe Patti, Markus Lucerna, Ladislav Pecen, Jolanta M Siller-Matula, Ilaria Cavallari

J Am Heart Assoc· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF.
Giuseppe Patti, Markus Lucerna, Ilaria Cavallari, Elisabetta Ricottini, Giulia Renda

J Am Coll Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells.
Gernot Schabbauer, Bernhard Schweighofer, Diana Mechtcheriakova, Markus Lucerna, Bernd R Binder

Thromb Haemost· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment.
Markus Lucerna, Alma Zernecke, Ramon de Nooijer, Saskia C de Jager, Ilze Bot

Blood· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth.
Markus Lucerna, Jiri Pomyje, Diana Mechtcheriakova, Alexandra Kadl, Florian Gruber

Cancer Res· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression.
Florian Gruber, Peter Hufnagl, Renate Hofer-Warbinek, Johannes A Schmid, Johannes M Breuss, Markus Lucerna

Blood· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells.
Markus Lucerna, Diana Mechtcheriakova, Alexandra Kadl, Gernot Schabbauer, Romana Schäfer

J Biol Chem· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis